Pharmaceutical

AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial

The company stock was down by over 22.7% in premarket trading as AN2 shared trial termination plans for epetraborole.

Aug 11, 2024 - 04:00
AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial
The company stock was down by over 22.7% in premarket trading as AN2 shared trial termination plans for epetraborole.
Read the original article

Tags:

Previous Article

Eli Lilly boosts sales forecast by $3bn as diabetes and weight loss drugs propel...

Next Article

Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Indian pharma manufacturing: rising investment in Andhra Pradesh

Indian pharma manufacturing: rising investment in Andhr...

Apr 4, 2023

FDA accepts Astellas’ sNDA for CRESEMBA to treat fungal infections

FDA accepts Astellas’ sNDA for CRESEMBA to treat fungal...

Aug 12, 2023

MSD ventures into fibroblast therapies with $1.9bn deal with Mestag

MSD ventures into fibroblast therapies with $1.9bn deal...

Oct 10, 2024